Travel medicine and pre-travel advice for children

Overview & Definition

Picture a ten-year-old girl brought to the general paediatric clinic six weeks before the family flies to visit grandparents in rural Bangladesh. She has not seen a doctor in two years, her immunisation record is incomplete, and her parents are unsure whether she needs "the malaria tablets". The easy assumption is that this is a quick vaccine visit; the correct response is a structured conversation that re-weights every ordinary childhood risk against the destination she is about to enter. Pre-travel advice for children is a risk-reduction encounter, not a vaccine checklist, and its job is to stop this child from returning in six weeks with falciparum malaria. [2]

The defining principle is that the travelling child carries two layers of risk simultaneously. The first is the familiar background of childhood — the routine immunisations she may have missed, the chronic conditions she lives with, the developmental stage that shapes her behaviour and her ability to report symptoms. The second is the destination-specific layer — the vector-borne, food-borne and environmental pathogens that her non-immune immune system has never met. A sound pre-travel consultation layers these and produces a written plan, rather than handing over a prescription and hoping for the best. [1] [11]

What makes this a fellowship-level topic is that the highest-yield interventions are also the ones most often missed. The GeoSentinel surveillance network has shown, again and again, that imported paediatric infection concentrates in a single group — the visiting-friends-and-relatives family — and that this group is the least likely to have sought pre-travel advice. The skill is therefore not only to advise the family in front of you, but to recognise the high-risk family in the waiting room and to build a system, through primary care and community outreach, that reaches them before they book the flight. [2] [11]

Classification

The most useful way to classify pre-travel risk is by the combination of destination burden, type of travel and the child, because that composite score drives the intensity of every recommendation. A low-risk destination for a healthy, fully-immunised school-age child on a short tourist trip to an urban centre needs little beyond routine vaccine catch-up and sun safety. A high-risk destination for an incompletely-immunised infant visiting a rural village in a malarious region for a month needs the full four-lane plan, timed weeks in advance. [1] [12]

The destination is graded by the local burden of vaccine-preventable and vector-borne disease. Sub-Saharan Africa and the Oceania melanesian countries carry the highest falciparum malaria burden; South and Southeast Asia lead in dengue, enteric fever and Japanese encephalitis; the meningitis belt of sub-Saharan Africa carries seasonal meningococcal risk; and a handful of countries in equatorial Africa and South America mandate yellow fever vaccination for entry. Dengue now affects close to four hundred million people a year, and its reach into previously unaffected regions means the bite-avoidance message matters even where it was once unnecessary. [7] [6]

The type and duration of travel modify the baseline destination risk. Backpackers, rural visitors, trekkers and those staying in unscreened accommodation or with open food and water sources convert a moderate-risk destination into a high-risk exposure. The single most important modifier is the visiting-friends-and-relatives trip: these families stay longer, travel more intensely, have higher rural exposure, and are less likely to have taken prophylaxis, which is why they account for a disproportionate share of imported malaria and typhoid. Long duration multiplies the cumulative risk of any exposure. [2] [3]

The child raises the bar on every destination. An infant under two, a child with incomplete vaccinations, an asplenic or immunocompromised child, and a pregnant adolescent all convert a moderate-risk exposure into a high-risk one, because their immune systems either cannot tolerate the standard interventions or cannot contain the infection if it occurs. Age also governs which interventions are even available: yellow fever vaccine is contraindicated under nine months, doxycycline prophylaxis is avoided under eight years, and several travel vaccines are licensed only above a minimum age, which means a young child travelling to a high-risk region may need an altered itinerary rather than an unsafe vaccine. [12] [5]

Epidemiology & Risk Factors

The epidemiology of imported paediatric infection is dominated by two observations. First, most of it is preventable through vaccination, chemoprophylaxis and behaviour, which means every case that reaches a high-income hospital represents a failure of the pre-travel system rather than an unavoidable act of nature. Second, the preventable cases concentrate predictably in one group, which makes targeted outreach both feasible and high-yield. [1] [11]

The visiting-friends-and-relatives family is the central epidemiological fact of this topic. Migrant families who take their Australia-born or UK-born children back to a malarious or typhoid-endemic country of origin account for a disproportionate share of imported malaria and enteric fever. Their children are non-immune to the local pathogens, they stay longer and travel more intensely than tourists, and they are the group least likely to have sought or completed pre-travel advice, because the parents underestimate the risk to a child who has never lived in the endemic setting. The systematic review of imported infectious disease in children returning to Europe confirms that the burden falls heaviest on this group. [2] [11]

Dengue has reshaped the pre-travel landscape for any family bound for the tropics. The global burden model published by Bhatt and colleagues estimated close to four hundred million infections a year, with roughly a quarter of the world's population living in suitable transmission zones, and the disease has expanded into regions where it was once rare. There is no licensed paediatric chemoprophylaxis for dengue and no specific treatment, which places the entire weight of prevention on rigorous daytime insect-bite avoidance — the message that must reach every family heading to a dengue-endemic region. [7]

Enteric fever remains common in returned travellers from South Asia, and antimicrobial resistance has changed the pre-travel conversation about standby therapy. Extensively drug-resistant Salmonella Typhi, resistant to fluoroquinolones and often to third-generation cephalosporins, is now prevalent in South Asia, so the self-treatment plan for a febrile child returning from that region cannot rely on a fluoroquinolone. The GeoSentinel analysis of enteric fever in international travellers documented the rising resistance and the geographic pattern, underlining that the pre-travel antibiotic message is a destination-driven one. [9] [8]

Risk is also shaped by the vaccine refusal that the Global TravEpiNet cohort documented: a meaningful proportion of families decline one or more recommended travel vaccines, which means the consultation is as much a risk-communication and shared-decision conversation as a prescribing encounter. The clinician who understands why families hesitate, and who addresses the specific concern rather than repeating the schedule, is the one whose families leave protected. [5]

Pathophysiology

The travelling child acquires infection through four distinct transmission routes, and understanding each route points to the intervention that blocks it. The discipline of pre-travel advice is to match every plausible exposure to its preventive measure, rather than to treat travel as a generic risk. [6]

Vector-borne infection is the most decisional category because several of its members are life-threatening and at least partly preventable. The anopheline mosquito transmits malaria, with Plasmodium falciparum causing the cytoadherence, sequestration and acidosis that kill children. The Aedes mosquito, a daytime biter, transmits dengue, Zika and chikungunya; the night-biting Culex transmits Japanese encephalitis in rural Asia; and ticks and mites transmit the spotted-fever and scrub-typhus rickettsiae. The preventive logic follows the vector: malaria is reduced by chemoprophylaxis plus evening bite avoidance, dengue by daytime bite avoidance alone, and Japanese encephalitis by vaccine for rural, prolonged-stay travellers. [6] [7]

Food-borne and water-borne infection follows the faecal-oral route and accounts for much of the preventable morbidity in young travellers. Salmonella Typhi and Paratyphi cause enteric fever; hepatitis A and E cause liver disease; and the bacterial, viral and protozoal causes of travellers' diarrhoea account for the single largest share of travel-related illness in children. The preventive logic is vaccination where a vaccine exists (typhoid, hepatitis A) and behavioural protection everywhere else — the cook-it, peel-it, boil-it-or-forget-it rule, safe water, and hand hygiene. [1] [9]

Respiratory and contact transmission brings influenza, tuberculosis, measles and meningococcal disease into the travelling child's differential, and the intensity of crowding at airports, on long-haul flights and in mass gatherings raises the exposure above the home baseline. Measles outbreaks among unvaccinated travellers are a recurring public-health problem, which is why the pre-travel encounter is a powerful moment to catch up the routine measles-mumps-rubella vaccine. The meningococcal quadrivalent vaccine is relevant for the Hajj and for the African meningitis belt. [1] [5]

Animal and environmental exposure produces rabies from dog and bat bites, schistosomiasis from freshwater, and soil-transmitted helminths from barefoot walking. Rabies is almost uniformly fatal once symptoms begin, so pre-exposure prophylaxis is offered to children with high-risk itineraries, and every family receives the message to wash and seek urgent post-exposure care after any animal bite. Schistosomiasis is prevented by avoiding freshwater swimming in endemic areas. [1] [12]

Clinical Presentation

The "presentation" of the pre-travel encounter is the family who walks in before departure, and the clinician's task is to take a structured travel history that is every bit as deliberate as the one taken of the febrile returned child. Ask the destination in detail — country, region, urban versus rural, and whether specific high-risk zones such as the meningitis belt or a yellow-fever-endemic area are involved. Ask the dates and duration of travel, the time remaining before departure, and the reason for travel, because the visiting-friends-and-relatives trip flags the highest risk at once. [1] [2]

Ask the planned activities in detail — trekking, swimming in freshwater, animal contact, barefoot walking, caving, mass gatherings, and the standard of accommodation and food preparation. Each activity maps to a specific preventive measure, and a family who knows what their child will actually do is a family who can be advised precisely rather than generically. Then take the child's history: current health, chronic conditions, medication, allergies, immunisation status, and any prior travel and prior travel-related illness. [12]

Examine the child where relevant — a brief growth and developmental check, confirmation of the immunisation record, and attention to any chronic condition that the destination will stress. An asthma action plan for the trekking child, an adrenal-crisis plan for the child on steroid replacement, a sickle-cell plan for the child at altitude — each chronic condition translates into a destination-specific risk that the pre-travel encounter is the moment to anticipate. [12]

The encounter is also a risk-communication moment, not only a prescribing one. Families refuse vaccines for reasons that are often specific and addressable, and the clinician who asks about hesitancy and addresses the particular concern — rather than restating the schedule — achieves higher uptake. Frame the advice around what the family is doing well, correct the gap, and give the reasons in plain language, because a family that understands the rationale takes the prophylaxis and keeps taking it. [5]

Differential Diagnosis

The "differential" in a pre-travel encounter is the list of destination-specific risks the child might acquire, ranked by probability and consequence for that destination, that duration and that child. The clinician holds this list in mind while building the plan, so that every plausible exposure has a matched intervention. The framework is the same one used for the returned traveller, but applied prospectively to prevent rather than to diagnose. [1] [6]

For a child bound for sub-Saharan Africa or the Oceania melanesian region, falciparum malaria dominates the life-threatening risks, and the plan centres on chemoprophylaxis, bite avoidance and the fever-after-travel rule. Yellow fever vaccination may be required for entry to parts of equatorial Africa, and the meningococcal quadrivalent vaccine is relevant for the meningitis belt. For a child bound for South or Southeast Asia, dengue, enteric fever and Japanese encephalism rise up the list, with typhoid vaccination, daytime bite avoidance and food-and-water hygiene as the anchors. [7] [9]

For the rural, long-stay or VFR traveller, the list widens to rabies, schistosomiasis, soil-transmitted helminths, hepatitis A and E, and tuberculosis, each with its matched intervention. For the adventure traveller, altitude illness joins the list and carries its own pharmacology. The common, non-tropical risks — influenza, measles in the unvaccinated, food poisoning, road trauma, drowning and sun damage — are numerically dominant and must not be forgotten in the hunt for the exotic, because the most common serious harm to a travelling child is often an injury, not an infection. [1] [12]

Clinical & Bedside Assessment

The bedside assessment in a pre-travel encounter is the structured interview that builds the risk score, and its single highest-yield element is the question every family should be asked but few are: have you ever travelled to visit family and relatives abroad, and do you plan to? This question surfaces the VFR family in the primary-care waiting room, where the highest-yield pre-travel advice can be delivered long before the flight is booked, rather than in the emergency department weeks after return. [2] [11]

Assess the child's immune and developmental status systematically. Confirm the routine immunisation record and plan catch-up doses that can be accelerated where a child is travelling imminently, because the pre-travel encounter is one of the most powerful catch-up opportunities in all of primary care. Identify the conditions that change the risk calculus — asplenia, immunocompromise, chronic cardiac, renal or respiratory disease, pregnancy in the adolescent — because each one alters both the vaccine choice and the threshold for prophylaxis. [12] [5]

Assess the family's health literacy, language, and likely adherence, because a prescription that is not taken is worse than no prescription at all. Use a trained interpreter where the family's first language is not English, because the subtleties of prophylaxis timing and the fever-after-travel rule are too important to lose in translation. Assess the family's access to healthcare at the destination and their travel insurance and medevac arrangements, because the response kit depends on what care is realistically available if the child becomes unwell abroad. [12]

Investigations

There is no routine panel of investigations for the pre-travel encounter; testing is driven by the child's history and the planned interventions. The most common investigation is simply the documentation of the immunisation record, because the catch-up plan depends on what the child has already received and when. Where the record is uncertain, serology for hepatitis B, varicella or measles may clarify immune status, but serology should not delay catch-up vaccination in a child travelling imminently. [12]

For children with chronic conditions, a brief review of recent bloods may be warranted to confirm stability before a demanding itinerary — the child with nephrotic syndrome on immunosuppression, the child with cyanotic heart disease heading to altitude, the child with sickle cell disease whose splenic function and haemoglobin must be known. These tests are condition-specific rather than travel-generic, and their purpose is to confirm the child is fit for the planned exposure. [12]

Tuberculosis screening before and after travel is relevant for the long-stay traveller to a high-prevalence region, and the pre-travel encounter is the moment to record a baseline tuberculin or interferon-gamma-release assay where one will be needed on return. For the child receiving live vaccines, a pregnancy test in the sexually active adolescent and a check for immunocompromise ensure the vaccines are safe to give. Beyond these, the investigations follow the child, not the destination. [1] [5]

Management — Resuscitation

The resuscitation equivalent in a pre-travel encounter is the immediate gap — the protection the child lacks right now and cannot afford to miss. The first priority is to confirm that the child will not depart without the two highest-stakes interventions: age-appropriate malaria chemoprophylaxis for a chloroquine-resistant destination, and catch-up of any missing routine immunisations, especially measles, before travel to an endemic region. A child who leaves without these is the child most likely to return in extremis. [10] [1]

Where departure is imminent, compress the timeline without abandoning the plan. Accelerated vaccine schedules can deliver some protection before travel, a first dose of a multi-dose series confers at least partial immunity, and the message that last-minute advice is still worthwhile must be given to the family who arrives the day before departure. The behavioural and prophylaxis lanes can be delivered in a single visit, even when the vaccine lane cannot be completed. [12]

Address the contraindications that change the itinerary rather than the vaccine. A child under nine months facing a yellow-fever-certified destination needs a medical waiver and a route change, not a contraindicated vaccine. A child under eight years facing a doxycycline-preferred region needs atovaquone-proguanil instead. The resuscitation move is to make the age-and-contraindication check before any prescription leaves the room, because the wrong drug or the unsafe vaccine is the fastest way to harm a travelling child. [12] [5]

Management — Definitive & Stepwise

Definitive pre-travel management runs in four parallel lanes, and the discipline is to deliver all four rather than to fixate on vaccines alone. The immunisation lane delivers routine catch-up plus the travel-specific vaccines the destination requires or recommends, timed for seroconversion. The prophylaxis lane delivers chemoprevention — malaria, and altitude where relevant. The behavioural lane delivers the non-pharmacologic barriers: insect avoidance, food and water safety, sun protection, road and water safety. The response-kit lane delivers standby therapy and the fever-after-travel safety net. [1] [12]

[1]

In the immunisation lane, the age thresholds are examinable and decisional. Yellow fever vaccine is given from nine months where a certificate is required, and is contraindicated below that age, in pregnancy where avoidable, and in the immunocompromised or thymus-disordered child. Typhoid vaccine comes as an injectable Vi conjugate or polysaccharide from two years and an oral live attenuated form from six years. Hepatitis A vaccine is given from one year, with immunoglobulin offered to the infant under one year travelling to a high-risk region. The Japanese encephalitis vaccine (Ixiaro) is licensed from two months for rural-Asia travellers with prolonged or intense exposure, and the Global TravEpiNet analysis documented its real-world use in travel clinics. Rabies pre-exposure prophylaxis is offered to children with high-risk itineraries because paediatric rabies is almost always transmitted by a dog bite the family may not witness or report. [4] [12]

In the prophylaxis lane, the malaria drug is chosen by the child's age, the destination's resistance pattern, and the family's likely adherence. Atovaquone-proguanil is the default for young children travelling to chloroquine-resistant regions, because it is well tolerated, requires only one day of pre-exposure and seven days of post-travel dosing, and is licensed from five kilograms. Doxycycline is avoided under eight years; mefloquine is an alternative but carries neuropsychiatric contraindications and a longer lead-in time. The adherence message — start before exposure, continue through and after return, take with food — is as important as the drug choice, because a prophylaxis regimen not completed is the commonest reason for breakthrough infection. [10] [1]

In the behavioural lane, insect-bite avoidance is the only protection against dengue and Zika and a vital adjunct to malaria prophylaxis. Recommend a repellent of proven efficacy such as DEET (up to 50 per cent) or picaridin, applied to exposed skin, permethrin-treated clothing and bed nets, and avoidance of standing water where mosquitoes breed. Food and water safety follows the cook-it, peel-it, boil-it-or-forget-it rule, with bottled or filtered water and no ice. Sun protection, hand hygiene, road and traffic safety and water safety are the non-infective protections that prevent the most common serious harms to travelling children. [7] [12]

In the response-kit lane, give the family oral rehydration salts and a standby antidiarrhoeal plan, with azithromycin rather than a fluoroquinolone for severe travellers' diarrhoea acquired in South Asia, where resistant strains predominate. Write down the fever-after-travel rule and the destination in the family's language, confirm travel insurance and medevac arrangements, and identify a reliable healthcare contact at the destination. The response kit converts the pre-travel encounter from advice into a written plan the family can act on under stress. [9] [12]

Specific Subtypes & Scenarios

The visiting-friends-and-relatives family is the single most important subtype, and it deserves a targeted approach in every setting. These families are the highest-risk group for imported malaria and typhoid, yet they are the least likely to have sought pre-travel advice, because the parents underestimate the risk to a non-immune child born in Australia or New Zealand. The fix is twofold: in primary care, ask the VFR question of every family so the group is surfaced; and in the travel clinic, give a full four-lane plan with extra attention to prophylaxis adherence and the fever-after-travel rule. The Bacaner analysis of travel medicine for North American immigrants visiting friends and relatives established this group as the central epidemiological fact of imported paediatric infection. [2]

The infant and the very young child present the age-threshold problem most acutely. Yellow fever vaccine is contraindicated under nine months, doxycycline prophylaxis under eight years, and several travel vaccines are licensed only above a minimum age, which means a young child facing a high-risk destination may need an altered itinerary rather than an unsafe intervention. Hepatitis A vaccine is not licensed under one year, so the travelling infant receives immunoglobulin instead, and the family is advised on food and water safety with particular stringency. The developmental stage also shapes the behavioural advice: the toddler who cannot report a bite or a symptom needs a lower threshold for the family to seek care. [12]

The immunocompromised or asplenic child converts a moderate destination into a high-risk one and faces vaccine contraindications as well. Live vaccines — yellow fever, oral typhoid, measles-mumps-rubella — are generally avoided in significant immunocompromise, and the asplenic child is at catastrophic risk of severe malaria and of encapsulated-bacterial sepsis, which makes chemoprophylaxis and antibiotic standby non-negotiable for any endemic destination. The pre-travel plan for these children is built with the immunology or infectious-diseases team, and the itinerary may need to change where the safe interventions are not available. [5] [12]

The adolescent traveller faces a different risk profile, dominated by behaviour — alcohol and drug use, sexual exposure, adventurous activity, and the risk of injury and trauma that overshadows infection in this age group. The pre-travel encounter for the adolescent includes sexual-health advice, emergency contraception, a clear message about rabies and animal-bite management, and attention to mental-health and risk-taking, alongside the standard vaccine and prophylaxis plan. The pregnant adolescent adds the further constraint that several drugs and live vaccines are contraindicated, so the destination and the itinerary must be chosen around the pregnancy. [12]

The last-minute traveller — the family who arrives the day before departure — cannot complete a primary vaccine series, yet the visit is still worthwhile. Deliver the prophylaxis and behavioural lanes in full, give the first dose of every available vaccine, and arrange the remaining doses to be completed at the destination or on return. The message is that partial protection plus behaviour plus a fever plan is far better than nothing, and that the family should still seek pre-travel advice even when the timing is imperfect. [12]

Complications & Pitfalls

The cardinal pitfall is treating the pre-travel encounter as a vaccine visit. A family who receives a handful of vaccines but no chemoprophylaxis, no behavioural advice and no fever-after-travel rule leaves believing they are protected when they are not. The structural defence is to run all four lanes every time, because the vaccine lane is only one quarter of the protection and the lanes that families skip are the ones that matter most. [1] [12]

The second pitfall is the wrong chemoprophylaxis for the age. Doxycycline under eight years, mefloquine in a child with a neuropsychiatric history, and a drug started too late to reach protective levels are all avoidable errors that flow from a consultation that did not check the age and the adherence. The age-and-contraindication check is a non-negotiable step before any prophylaxis prescription leaves the room. [10]

The third pitfall is giving a contraindicated live vaccine. Yellow fever under nine months, oral typhoid under six years or in the immunocompromised child, and live vaccines in pregnancy or immunocompromise are errors with real consequences, and they are avoided by a systematic check of the child's age, immune status and pregnancy status before any live vaccine is drawn up. [12] [5]

The fourth pitfall is missing the VFR family. The family who is never asked the visiting-friends-and-relatives question is the family whose child returns with falciparum malaria, because they never received the prophylaxis, the bite-avoidance message or the fever rule. Asking the question in primary care, and building outreach to migrant communities, is the system-level fix that prevents the highest-yield cases. [2] [11]

The fifth pitfall is no fever-after-travel safety net. The family who is vaccinated, prophylaxed and behaviourally advised but who is never told the fever rule is the family whose child develops malaria and is treated for influenza at the first unscheduled visit. The rule must be written, in the family's language, and the destination must be stated at every healthcare contact after return. [10] [1]

Prognosis & Disposition

The prognosis of the travelling child is overwhelmingly good when the pre-travel plan is delivered in full, taken as advised, and supported by a clear response kit. Most children travel without incident, and those who acquire a travel-related infection do well when it is recognised and treated promptly. The children who do badly are the ones whose plan was incomplete, whose prophylaxis was not taken, or whose family did not know the fever rule — which is why the quality of the encounter, not the destination, is the decisive variable. [1] [11]

Disposition from the pre-travel encounter is a written plan and a follow-up arrangement, not a discharge. The plan documents the vaccines given and due, the prophylaxis with its start and stop dates, the behavioural advice, and the response kit including the fever-after-travel rule in the family's language. The follow-up arranges the remaining vaccine doses and confirms, before departure, that the prophylaxis was started and tolerated. A family who leaves with a written plan and a follow-up date is a family whose adherence the clinician has supported rather than assumed. [12]

For the family who does not attend, or who arrives too late for a complete plan, the prognosis depends on the partial protection delivered and on the quality of the destination-side and return-side safety net. The message to every clinician is that last-minute advice is still worthwhile, that partial protection plus behaviour plus a fever plan reduces harm, and that the absence of a perfect plan is never a reason to give no plan at all. [12]

Special Populations

The visiting-friends-and-relatives family deserves targeted outreach rather than passive clinic attendance, because they are the group most often missed and the group who carries the greatest burden of imported disease. Primary-care teams can identify these families at routine visits, flag planned travel, and arrange a pre-travel consultation weeks before departure. Community-level outreach to migrant communities, delivered in the family's language and by trusted messengers, reaches the families who would never walk into a travel clinic on their own. [2] [11]

The newly arrived migrant, refugee or asylum-seeking child may travel back to a country of origin soon after settlement, before the family has engaged with primary care, and may carry incomplete routine immunisations on top of the travel-specific risk. Frame the assessment as comprehensive care — catch-up immunisation, chronic-disease review, and a pre-travel plan — and use trained interpreters, because the travel and exposure details are too important to lose in translation. [11]

The Indigenous child travelling to or from remote communities may face different baseline infectious risk and access barriers to pre-travel services, vaccines and post-travel care. Rural and remote families need a low threshold for outreach, and the pre-travel plan must account for the distance to reliable healthcare at the destination and on return. [1]

The immunocompromised or asplenic child requires a coordinated plan built with the relevant subspecialty team, because the live vaccines are contraindicated and the threshold for prophylaxis is lower. The itinerary may need to change where the safe interventions are not available, and the family needs a clear, written response kit that accounts for the heightened severity of any acquired infection. [5] [12]

The infant and the pre-verbal child need the most conservative plan, because they cannot report symptoms, several interventions are age-limited, and the threshold for the family to seek care at the destination is lowest. Advise stringently on food, water and bite avoidance, use immunoglobulin where the hepatitis A vaccine is not licensed, and consider an altered itinerary where the safe interventions cannot reach the risk. [12]

Evidence, Guidelines & Regional Differences

The evidence base for pre-travel advice rests on three pillars. The first is the GeoSentinel surveillance network, whose analyses define the probability of disease by destination, traveller type and syndrome, and which established the visiting-friends-and-relatives family as the highest-risk group. The Freedman spectrum-of-disease paper, the Bacaner analysis of VFR travel, the Angelo analysis of illness in student travellers, and the Niestępski systematic review of imported disease in children returning to Europe together give the clinician a data-driven prior for any given travelling child. [1] [2] [3] [11]

The second pillar is the Global TravEpiNet cohort, whose analyses describe real-world pre-travel practice: the Deshpande study of Japanese encephalitis vaccine use and the Lammert study of travel-vaccine refusal show how vaccines are actually used and refused in clinic, and they underline that the encounter is a risk-communication exercise as much as a prescribing one. These studies are the evidence base for the adherence-and-hesitancy lens that a fellowship answer must bring. [4] [5]

The third pillar is the destination-driven resistance and burden evidence. The Bhatt dengue global-burden model redefined the scale of dengue and its reach into previously unaffected regions, the Hagmann GeoSentinel analysis of enteric fever documented the rising prevalence of extensively drug-resistant Salmonella Typhi in South Asia, and the Britto systematic review clarified that paediatric typhoid presents atypically. The Kiang update on imported malaria treatment anchors the post-travel pathway that the pre-travel plan exists to prevent, and the Jensenius analysis of life-threatening tropical disease defines the severity stakes. [7] [9] [8] [10] [6]

Regional differences are real and decisional. In Australia and New Zealand, the family travelling to Papua New Guinea, the Solomon Islands or Vanuatu carries high falciparum risk, and chemoprophylaxis and artesunate availability must be assured; the family travelling to Southeast Asia may encounter dengue and artemisinin-resistant malaria; the family travelling to South Asia may encounter XDR typhoid. The CDC Yellow Book, the WHO International Travel and Health guidance, and the national immunisation handbooks translate the global evidence into local practice, and the fellowship candidate is expected to apply them to a named destination rather than to recite them generically. [12] [1]

Exam Pearls

Travel medicine is an examination favourite because it rewards structured reasoning over factual recall. The single highest-yield frame is the four-lane plan — immunisation, prophylaxis, behavioural, response kit — delivered to a risk score built from the destination, the type of travel and the child. State the four lanes in every answer, and the examiner knows you have not reduced the encounter to a vaccine visit. [1] [12]

The age thresholds are examinable and high-yield. Yellow fever vaccine is contraindicated under nine months and in the immunocompromised or thymus-disordered child; doxycycline prophylaxis is avoided under eight years; atovaquone-proguanil is the default for young children in chloroquine-resistant regions; hepatitis A vaccine is licensed from one year, with immunoglobulin for the infant under one. The four-to-six-week timing for seroconversion is the other number to know, alongside the message that last-minute advice is still worthwhile. [10] [5]

The visiting-friends-and-relatives family is the highest-risk group and the one most often missed — name them in every answer, explain why they are high-risk, and describe the targeted outreach that reaches them. The fever-after-travel rule — a febrile child within months of return from a malaria-endemic area must seek care and state the destination — is the single most important safety-net message and the one the examiner expects to hear. [2] [11]

For the orals and the long case, be ready to defend a chemoprophylaxis choice by age and destination, to handle the yellow-fever-certified destination for the child under nine months with a waiver and a route change, and to address vaccine hesitancy as a risk-communication task rather than a compliance lecture. Know that XDR typhoid from South Asia has reshaped the standby-antibiotic message, that dengue prevention rests entirely on daytime bite avoidance, and that the most common serious harm to a travelling child is often an injury, not an infection. [9] [7]

References

1. [1]Freedman DO; Weld LH; Kozarsky PE; Fisk T; et al Spectrum of disease and relation to place of exposure among ill returned travelers N Engl J Med, 2006.PMID 16407507
2. [2]Bacaner N; Stauffer B; Boulware DR; Walker PF; et al Travel medicine considerations for North American immigrants visiting friends and relatives JAMA, 2004.PMID 15199037
3. [3]Angelo KM; Haulman NJ; Terry AC; Leung DT; et al Illness among US resident student travellers after return to the USA: a GeoSentinel analysis, 2007-17 J Travel Med, 2018.PMID 30202952
4. [4]Deshpande BR; Rao SR; Jentes ES; Hills SL; et al Use of Japanese encephalitis vaccine in US travel medicine practices in Global TravEpiNet Am J Trop Med Hyg, 2014.PMID 25070999
5. [5]Lammert SM; Rao SR; Jentes ES; Fairley JK; et al Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet J Travel Med, 2016.PMID 27799502
6. [6]Jensenius M; Han PV; Schlagenhauf P; Schwartz E; et al Acute and potentially life-threatening tropical diseases in western travelers--a GeoSentinel multicenter study, 1996-2011 Am J Trop Med Hyg, 2013.PMID 23324216
7. [7]Bhatt S; Gething PW; Brady OJ; Messina JP; et al The global distribution and burden of dengue Nature, 2013.PMID 23563266
8. [8]Britto C; Pollard AJ; Voysey M; Blohmke CJ An Appraisal of the Clinical Features of Pediatric Enteric Fever: Systematic Review and Meta-analysis of the Age-Stratified Disease Occurrence Clin Infect Dis, 2017.PMID 28369224
9. [9]Hagmann SHF; Angelo KM; Huits R; Plewes K; et al Epidemiological and Clinical Characteristics of International Travelers with Enteric Fever and Antibiotic Resistance Profiles of Their Isolates: a GeoSentinel Analysis Antimicrob Agents Chemother, 2020.PMID 32816733
10. [10]Kiang KM; Bryant PA; Shingadia D; Ladhani S; et al The treatment of imported malaria in children: an update Arch Dis Child Educ Pract Ed, 2013.PMID 23171589
11. [11]Niestępski J; Baran JM; Waszak Z; Jarzębska J; et al Epidemiology and Spectrum of Imported Infectious Diseases in Children and Adolescents Returning to Europe: A Systematic Review Pathogens, 2026.PMID 42347233
12. [12]Halsey ES; Angelo KM; Barnett ED; Chen LH; et al Traveling Safely with Infants and Children CDC Health Information for International Travel, 2025.PMID 41818599